Sunhee Chang
Inje University
AnatomyInternal medicineRadiologyEndocrinologyPhilosophyPathologyOncologyCellDermatologyPrecision medicineMolecular diagnosticsCytologyCyclin D1ImmunohistochemistryBiopsyLung cancerMesotheliomaCarcinomaLungErlotinibLarge cellEpidermal growth factor receptorLiquid biopsyGuidelineGefitinibDifferential diagnosisLesionAdenocarcinomaPathology studyNon small cellEgfr mutationCancer researchNecrosisThyroidMedicineBiomarker (medicine)StainingBiologyGastroenterology
33Publications
9H-index
213Citations
Publications 40
Newest
#1Sunhee Chang (Inje University)H-Index: 9
#2Hyo Sup Shim (Yonsei University)H-Index: 28
Last. Chang Hun Lee (PNU: Pusan National University)H-Index: 27
view all 10 authors...
Molecular biomarker testing is the standard of care for non-small cell lung cancer (NSCLC) patients. In 2017, the Korean Cardiopulmonary Pathology Study Group and the Korean Molecular Pathology Study Group co-published a molecular testing guideline which contained almost all known genetic changes that aid in treatment decisions or predict prognosis in patients with NSCLC. Since then there have been significant changes in targeted therapies as well as molecular testing including newly approved ta...
Source
#1Sunhee Chang (Inje University)H-Index: 9
#2Jae Young Hur (Konkuk University)H-Index: 1
Last. Wan Seop Kim (Konkuk University)H-Index: 16
view all 5 authors...
With advances in target therapy, molecular analysis of tumors is routinely required for treatment decisions in patients with advanced non-small cell lung cancer (NSCLC). Liquid biopsy refers to the sampling and analysis of circulating cell-free tumor DNA (ctDNA) in various body fluids, primarily blood. Because the technique is minimally invasive, liquid biopsies are the future in cancer management. Epidermal growth factor receptor (EGFR) ctDNA tests have been performed in routine clinical practi...
7 CitationsSource
#1Sunhee Chang (Inje University)H-Index: 9
#2Hyung Kyu Park (Konkuk University)H-Index: 9
Last. Se Jin Jang (UOU: University of Ulsan)H-Index: 44
view all 4 authors...
Background Assessment of programmed cell death-ligand 1 (PD-L1) immunohistochemical staining is used for treatment decisions in non-small cell lung cancer (NSCLC) regarding use of PD-L1/programmed cell death protein 1 (PD-1) immunotherapy. The reliability of the PD-L1 22C3 pharmDx assay is critical in guiding clinical practice. The Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists investigated the interobserver reproducibility of PD-L1 staining with 22C3 pharmDx in NSCL...
9 CitationsSource
#1Eun Kyung KimH-Index: 73
#2Kyung A. Kim (Yonsei University)H-Index: 4
Last. Hyo Sup Shim (Yonsei University)H-Index: 28
view all 7 authors...
Abstract Background Recent studies revealed MET exon 14 skipping ( MET ex14) as a biomarker that predicts the response to MET inhibitors in non–small-cell lung cancer (NSCLC). However, MET ex14 genomic alterations exhibit a highly diverse sequence composition, posing a challenge for clinical diagnostic testing. This study aimed to find a reasonable diagnostic assay for MET ex14 and identify its clinicopathologic implications. Materials and Methods We performed a comprehensive analysis of MET ex1...
35 CitationsSource
#1Yoon Jin Cha (Yonsei University)H-Index: 16
#2Ju Yeon Pyo (Yonsei University)H-Index: 7
Last. Sunhee Chang (Inje University)H-Index: 9
view all 12 authors...
We reviewed the current status of thyroid fine-needle aspiration cytology (FNAC) in Korea. Thyroid aspiration biopsy was first introduced in Korea in 1977. Currently, radiologists aspirate the thyroid nodule under the guidance of ultrasonography, and cytologic interpretation is only legally approved when a cytopathologist makes the diagnosis. In 2008, eight thyroid-related societies came together to form the Korean Thyroid Association. The Korean Society for Cytopathology and the endocrine patho...
7 CitationsSource
#1Hyo Sup Shim (Yonsei University)H-Index: 28
#2Yoon-La Choi (SMC: Samsung Medical Center)H-Index: 61
Last. Se Jin Jang (UOU: University of Ulsan)H-Index: 44
view all 11 authors...
: Targeted therapies guided by molecular diagnostics have become a standard treatment of lung cancer. Epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements are currently used as the best predictive biomarkers for EGFR tyrosine kinase inhibitors and ALK inhibitors, respectively. Besides EGFR and ALK, the list of druggable genetic alterations has been growing, including ROS1 rearrangements, RET rearrangements, and MET alterations. In this situation, ...
20 CitationsSource
#1Song-Hee Han (Inje University)H-Index: 1
#2Mee Joo (Inje University)H-Index: 16
Last. Sunhee Chang (Inje University)H-Index: 9
view all 4 authors...
BACKGROUND: Although surgical resection with chemotherapy is considered effective for patients with advanced gastric cancer, it remains the third leading cause of cancer-related death in South Korea. Several studies have reported that mesothelial markers including mesothelin, calretinin, and Wilms tumor protein 1 (WT1) were positive in variable carcinomas, associated with prognosis, and were evaluated as potential markers for targeted therapy. The aim of this study was to assess the immunohistoc...
11 CitationsSource
#1Kyueng-Whan Min (Hanyang University)H-Index: 16
#2Wan Seop Kim (Konkuk University)H-Index: 16
Last. Mi Jin Kim (Yeungnam University)H-Index: 5
view all 12 authors...
Background Testing for epidermal growth factor receptor (EGFR) mutation is an important process in the therapeutic plan of patients with lung cancer. Recently, MassARRAY, based on matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, has been shown to be a useful method for somatic mutation analysis with pyrosequencing and peptide nucleic acid clamping (PNAc).
6 CitationsSource
#1Song-Hee Han (Inje University)H-Index: 1
#2Mee Joo (Inje University)H-Index: 16
Last. Han-Seong Kim (Inje University)H-Index: 15
view all 4 authors...
Malakoplakia, meaning soft (malako) plaque (plakia), is a rare benign inflammatory lesion. The disease was initially described in the bladder by Michaelis and Gutmann [1] in 1902 and named by von Hansemann [2] in 1903. Since its initial description, many cases have been described in numerous anatomic locations including the genitourinary tract, gastrointestinal tract, pancreas, liver, oropharynx, retroperitoneum, thyroid gland, lymph nodes, lung, bone/joint, brain, skin, and other tissues [3-5]....
2 CitationsSource
#1Sunhee Chang (Inje University)H-Index: 9
#2Mee-Hye Oh (SCH: Soonchunhyang University)H-Index: 1
Last. Soon-Hee Jung (Yonsei University)H-Index: 9
view all 12 authors...
The differentiation of malignant mesotheliomas and benign mesothelial proliferations is crucial in determining patient care and prognosis. But, this distinction can be extremely difficult, particularly in small biopsies. Recently, insulin-like growth factor II mRNA-binding protein 3 (IMP3) and glucose transporter 1 (GLUT-1) have been reported as specific and sensitive markers in the distinction of mesotheliomas from benign mesothelial proliferations. The purpose of this study is to evaluate the ...
11 CitationsSource